Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment.

Park, Yewon; Na, Joo Young; Cho, Joo-Youn; Oh, Jaeseong; Rhee, Su-Jin

Park, Yewon; Na, Joo Young; Cho, Joo-Youn; Oh, Jaeseong; Rhee, Su-Jin.

Afiliación

Park Y; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Na JY; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Cho JY; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Oh J; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Rhee SJ; Department of Pharmacy, Wonkwang University College of Pharmacy, Iksan, South Korea.

Front Pharmacol ; 13: 842836, 2022.

Article en En | MEDLINE | ID: mdl-35721224

Palabras clave

COVID-19; anti-inflammatory agents; clinical trial design; cytokine release syndrome; drug development

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google